GLP-1s have redefined what is clinically achievable in metabolic health. For millions of individuals, they represent a vital, life-altering treatment for obesity, type 2 diabetes, MASH, obstructive sleep apnea, and cardiovascular risk reduction. A well-constructed cardiometabolic strategy recognizes the immense value of these medications for the right patients, in the right clinical context.